Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
Hepatology Research · 2023-05 · 53 (5) · 383-390
DOI: 10.1111/hepr.13892 ↗At a glance
Leitlinie in Hepatology Research, published online on 2023-03-10. Written by Kiyoshi Hasegawa and 27 co-authors. Institution: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. Cited 308 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: None..
Abstract (original language)
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
Subjects
Author keywords
Authors and institutions
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
- Department of Surgery, Hepato-Biliary Pancreatic Surgery Division, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
- Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Japan.
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
ORCID profiles: Kiyoshi Hasegawa, Nobuyuki Takemura, Takeyuki Watadani, Hiroaki Nagano, Etsuro Hatano, Kazuomi Ueshima, Kazuyoshi Ohkawa, Takuya Genda, Masafumi Ikeda, Satoshi Kobayashi, Takamichi Murakami
Funding
- None.
Cite
APA
Hasegawa, K., Takemura, N., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., Iijima, H., Ueshima, K., Ohkawa, K., Genda, T., Tsuchiya, K., Torimura, T., Ikeda, M., Furuse, J., Akahane, M., …, & committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan (2023). Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines). Hepatology Research, 53(5), 383-390. https://doi.org/10.1111/hepr.13892
Vancouver
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, et al. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines). Hepatology Research. 2023;53(5):383-390. doi:10.1111/hepr.13892
BibTeX
@article{Hasegawa2023,
author = {Hasegawa, Kiyoshi and Takemura, Nobuyuki and Yamashita, Tatsuya and Watadani, Takeyuki and Kaibori, Masaki and Kubo, Shoji and Shimada, Mitsuo and Nagano, Hiroaki and Hatano, Etsuro and Aikata, Hiroshi and Iijima, Hiroko and Ueshima, Kazuomi and Ohkawa, Kazuyoshi and Genda, Takuya and Tsuchiya, Kaoru and Torimura, Takuji and Ikeda, Masafumi and Furuse, Junji and Akahane, Masaaki and Kobayashi, Satoshi and Sakurai, Hideyuki and Takeda, Atsuya and Murakami, Takamichi and Motosugi, Utaroh and Matsuyama, Yutaka and Kudo, Masatoshi and Tateishi, Ryosuke and committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan, committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan},
title = {Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)},
journal = {Hepatology Research},
year = {2023},
volume = {53},
number = {5},
pages = {383--390},
doi = {10.1111/hepr.13892}
}
EUVIMED